Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a transplant drug stop HHT nosebleeds? small study tests sirolimus

NCT ID NCT05269849

Disease control Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested the safety and effectiveness of the oral drug sirolimus for reducing nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). Ten adults with moderate to severe nosebleeds took 2 mg of sirolimus daily for 3 months. Researchers tracked bleeding duration, side effects, and lab values to see if the drug could help control this common HHT symptom.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Mar 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 years 2. Clinical HHT diagnosis (8) or genetic diagnosis of HHT 3. Epistaxis at least 15 min per week. 4. COVID-19 Vaccine (2 doses) 5. Ability to give written informed consent, including compliance with the requirements of the study. Exclusion Criteria: 1. Allergy/intolerance to the study drug or related agents 2. Unstable medical illness 3. Acute infection 4. Creatinine \> ULN (upper limit of normal) 5. Liver transaminases (AST or ALT) \>= 2x ULN 6. Women participant who are pregnant or breastfeeding or plan to become pregnant during the duration of the study 7. Women of childbearing potential not on effective contraception. 8. Male participants of reproductive potential whose female partners are of childbearing potential and are not planning to use highly effective contraceptive method 9. Immunocompromised 10. History of malignancy 11. Known untreated dyslipidemia (20% above the ULN of total cholesterol and triglycerides) 12. Specific contra-indications for study drug (detailed in the product monograph)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epistaxis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Epistaxis hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epistaxis Hereditary hemorrhagic telangiectasia Nosebleeds

Contacts and locations

Locations

  • St. Michael's Hospital

    Toronto, Ontario, M5B 1W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.